Seminars in Radiation Oncology
Volume 19, Issue 3 , Pages 155-162 , July 2009

Functional and Metabolic Magnetic Resonance Imaging and Positron Emission Tomography for Tumor Volume Definition in High-Grade Gliomas

  • Christina I. Tsien, MD

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • Corresponding Author InformationAddress reprint requests to Christina I. Tsien, Department of Radiation Oncology, University of Michigan Medical Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109
    • ,
  • Yue Cao, PhD

      Affiliations

    • Department of Radiology, University of Michigan, Ann Arbor, MI
    • ,
  • Theodore S. Lawrence, MD, PhD

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

References 

  1. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16:1405–1409
  2. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20:1635–1642
  3. Lee SW, Fraass BA, Marsh LH, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999;43:79–88
  4. Tsien C, Moughan J, Michalski JM, et al. phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group trial 98-03. Int J Radiat Oncol Biol Phys. 2009;73(3):699–708
  5. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51:880–914
  6. Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006;64:892–897
  7. Thornton AF, Hegarty TJ, Ten HRK, et al. Three dimensional treatment planning of astrocytomas: A dosimetry study of cerebral irradiation. Int J Radiat Oncol Biol Phys. 1991;20:1309–1315
  8. Nelson SJ, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI. J Magn Reson Imaging. 2002;16:464–476
  9. Zakian KL, Koutcher JA, Ballon D, et al. Developments in nuclear magnetic resonance imaging and spectroscopy: Application to radiation oncology. Semin Radiat Oncol. 2001;11:3–15
  10. Pardo F, Aronen H, Kennedy D, et al. Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. Int J Radiat Oncol Biol Phys. 1994;30:663–669
  11. Grosu AL, Feldmann H, Dick S, et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys. 2002;54:842–854
  12. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511–519
  13. Meyer CR, Boes JL, Kim B, et al. Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal. 1997;1:195–206
  14. Petti PL, Kessler ML, Fleming T, et al. An automated image-registration technique based on multiple structure matching. Med Phys. 1994;21:1419–1426
  15. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas (A stereotactic PET study). J Neurosurg. 1993;79:853–858
  16. Grosu AL, Wiedenmann N, Molls M. Biological imaging in radiation oncology. Z Med Phys. 2005;15:141–145
  17. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–445
  18. Grosu AL, Weber WA, Riedel E, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:64–74
  19. Langen KJ, Muhlensiepen H, Holschbach M, et al. Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: Comparison with [3H]methyl]-L-methionine. J Nucl Med. 2000;41:1250–1255
  20. Torii K, Tsuyuguchi N, Kawabe J, et al. Correlation of amino acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med. 2005;19:677–683
  21. Sato N, Suzuki M, Kuwata N, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev. 1999;22:210–214
  22. Kracht LW, Friese M, Herholz K, et al. Methyl-[11C]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868–873
  23. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–1217
  24. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  25. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 2000;48:43–52
  26. Lee IH, Piert M, Gomez-Hassan D, et al. Association of (11)C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73(2):479–485
  27. Popperl G, Kreth FW, Herms J, et al. Analysis of 18F-fet PET for grading of recurrent gliomas: Is evaluation of uptake kinetics superior to standard methods?. J Nucl Med. 2006;47:393–403
  28. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol. 2007;25:4714–4721
  29. Cao Y, Sundgren PC, Tsien CI, et al. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol. 2006;24:1228–1235
  30. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther. 2003;2:497–507
  31. Preul MC, Caramanos Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med. 1996;2:323–325
  32. Li X, Lu Y, Pirzkall A, et al. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging. 2002;16:229–237
  33. Vigneron D, Bollen A, McDermott M, et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging. 2001;19:89–101
  34. Pirzkall A, Li X, Oh J, et al. 3D MRSI for resected high-grade gliomas before RT: Tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys. 2004;59:126–137
  35. McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002;97:794–802
  36. Park I, Tamai G, Lee MC, et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys. 2007;69:381–389
  37. Pirzkall A, McKnight TR, Graves EE, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys. 2001;50:915–928
  38. Graves EE, Nelson SJ, Vigneron DB, et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol. 2001;22:613–624
  39. Chan AA, Lau A, Pirzkall A, et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for grade IV glioma. J Neurosurg. 2004;101:467–475
  40. Rosen BR, Belliveau JW, Aronen HJ, et al. Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med. 1991;22:293–299
  41. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T, vol 1- weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–232
  42. Rempp KA, Brix G, Wenz F, et al. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology. 1994;193:637–641
  43. Cao Y, Shen Z, Chenevert TL, et al. An estimate of vascular permeability and cerebral blood volume using Gd-DTPA contrast enhancement and dynamic T2* weighted MRI. J Magn Reson Imaging. 2006;24(2):288–296
  44. Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med. 2004;51:961–968
  45. Cao Y, Nagesh V, Hamstra D, et al. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res. 2006;66:8912–8917
  46. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology. 1994;191:41–51
  47. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: Dynamic contrast-enhanced T2*-weighted MR imaging. Radiology. 1999;211:791–798
  48. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol. 1998;171:1479–1486
  49. Donahue KM, Krouwer HG, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med. 2000;43:845–853
  50. Kremer S, Grand S, Remy C, et al. Cerebral blood volume mapping by MR imaging in the initial evaluation of brain tumors. J Neuroradiol. 2002;29:105–113
  51. Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res. 2000;6:2189–2200
  52. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade. AJNR Am J Neuroradiol. 2000;21:891–899
  53. Provenzale JM, Wang GR, Brenner T, et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol. 2002;178:711–716
  54. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25:746–755
  55. Law M, Young RJ, Babb JS, et al. Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490–498
  56. Cao Y, Tsien CI, Nagesh V, et al. Clinical investigation survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT. Int J Radiat Oncol Biol Phys. 2006;64:876–885
  57. Sadeghi N, Salmon I, Tang BN, et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: Preliminary results. J Magn Reson Imaging. 2006;24:989–994
  58. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005;102:5524–5529
  59. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24):2029–2036
  60. Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387–3394
  61. Moffat BA, Chenevert TL, Lawrence TS, et al. Physiologic diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005;102:5524–5529

PII: S1053-4296(09)00020-4

doi: 10.1016/j.semradonc.2009.02.002

Seminars in Radiation Oncology
Volume 19, Issue 3 , Pages 155-162 , July 2009

Article Tools

* Image Usage & Resolution